SARS-Cov-2 infection in asthma patients treated with biologics

Authors:

Abstract
Background: Viral respiratory infections are associated with asthma exacerbations, still it is uncertain if asthma patients treated with biologics are more vulnerable to SARS-Cov-2 infection. Aim: Evaluation of characteristics and outcomes of COVID-19 disease in asthma patients treated with biologics. Methods: 27 asthma clinics from Greece provided data concerning demographic and functional characteristics, as well as medical treatments of patients treated with biologics. Patients were prospectively followed up and had a PCR test for confirmation of COVID-19 disease in case of suspected symptoms. Results: 541(352 female) patients receiving biologics (omalizumab 210, mepolizumab 321 and benralizumab 9 patients, respectively), mean age 57.3±14.4 years, were studied. In total, 14(2.6%) patients (8 female), mean age 58.6 years had a confirmed SARS-Cov-2 infection. 6/14, all female, were hospitalized due to severe disease, with mean length of hospital stay 15.8 days, while 1 received mechanical ventilation and died from severe COVID-19. Five of PCR+ patients (35.7%) experienced an asthma exacerbation, defined as asthma control deterioration requiring treatment with systemic steroids, while all others had clinical and radiological manifestation of pneumonia without loss of control. Administration of biologics was performed timely, apart from 1 case in which it was delayed according to physician’s decision. Conclusion: Our study confirm that COVID-19 is not more common in asthmatics treated with biologics compared to general population. However, more than a 1/3 experienced an asthma exacerbation, although in the majority infection did not result in loss of control and scheduled administration of biologics was not interrupted.